Lotte Biologics Expands CDMO Business with New ADC Facility in US and Global Contracts

LOTTE BIOLOGICS Bolstered its CDMO Expansion in North America and Asia

Announcement

Lotte Biologics’ CEO James Park is leveraging its growth as a global Contract development and manufacturing organization (CDMO) company. This year, the company has elevated its CDMO business expansion with the ADC (antibody-drug conjugate) completion that expanded its facilities at its Syracuse bio campus in the US, and also signed its first production contract.

Lotte’s Journey

Lotte Biologics entered the global CDMO market in 20222 by acquiring Bristol Myers Squibb’s (BMS) biologics manufacturing facility in Syracuse, New York. With this acquisition and integration into its workforce, Lotte Biologics ensures groundbreaking quality competition and standardized manufacturing capabilities. By centralizing investments, the company transformed itself into a tough, competitive CDMO potential to produce ADCs and antibodies by extending its potency to include new modality ADC production facilities. It is now a major commercial point globally.

Lotte Biologics invested up to USD 100 million into its Syracuse bio campus to strong advanced ADC production infrastructure, along with conjugation suites with its capacity of up to 1,000L. Further, it will establish its position as a robust North American production hub for future biologics. The site includes cross-contamination prevention systems, quality control, high-efficiency production lines, and advanced safety design. This is a response to the increasing demand for next-generation biologics.

Additionally, to this ADC infrastructure, Lotte is innovating its technology classification via its proprietary ADC platform, soluflex link™. This technology will enhance ADCs' hydrophilicity and linker-payload solubility, which will improve drug efficacy and stability. It is introduced to seamlessly contribute to various indications. With this initiative, Lotte Biologics targets to fulfill custom ADC production needs and ensure integrated competitiveness across technologies and facilities.

Current Status

Lotte Biologics is currently building a huge marketing bio campus in Songdo, Korea, with the first plant to be operational in 2027. Meanwhile, the Syracuse campus delivers as a one-stop CDMO hub from antibody to ADC in North America, and the Songdo site will operate as a massive production base, contrasting the huge manufacturing network. To fuel its CDMO potency, Lotte Biologics is initiating strategic collaborations with popular domestic and worldwide biotech companies across several domains, also it includes ADC platform development, contract development (CDO), and cell line development. The company is focusing on creating aligned, reliable services by merging mutual strengths with co-prosperity.

Learning from this strategy, the company is slowly uplifting its track record by safeguarding the contract manufacturing deals with the US-based global pharma companies, specifically listed European firms and biotech.